Extracorporeal membrane oxygenation in veno-arterial configuration (VA-ECMO) is a method widely used to support circulation during the most severe conditions of heart failure or refractory cardiac arrest. It frequently bridges this otherwise fatal status to recovery, therapeutic intervention or other circulatory support. However, the use of VA-ECMO in critical situations of severely impaired heart function is associated with specific limitations. One common complication is left ventricular overload and distention, primarily due to the increased afterload caused by extracorporeal blood flow. To date, various techniques have been proposed to decrease left ventricular distention and improve its function, including insertion of intra-aortic balloon pump or percutaneous left ventricular assist device, left atrial and left ventricular venting, or switch to surgically inserted left ventricular support with or without oxygenator. The present review summarizes current minimally invasive approaches to unload over-loaded left ventricle during VA-ECMO support.

Key Words: Cardiogenic shock; Extracorporeal membrane oxygenation; Heart failure; Left ventricular overload; Left ventricular unloading

Clinical Indications for VA-ECMO

Currently, there are no randomized controlled trials focused on the clinical outcomes of VA-ECMO. However, several analyses of registries and case series have demonstrated promising results for VA-ECMO therapy. The major indication for VA-ECMO placement is severe or rapidly progressing cardiogenic shock. Combes et al (1) reported experience from a group of 81 consecutive patients in whom VA-ECMO was inserted due to refractory cardiogenic shock. Thirty-four (42%) patients survived despite a predicted mortality rate of nearly 100% before VA-ECMO placement. Sheu et al (2) described a retrospective comparison of 219 VA-ECMO-treated individuals with cardiogenic shock due to myocardial infarction with an historical control group of 115 patients. They found a significantly higher 30-day survival rate in the VA-ECMO-treated group (60%) than in the control group (35%). Moreover, Beutheret et al (3) demonstrated that VA-ECMO can be inserted in patients with refractory cardiogenic shock in remote institutions and safely transferred on ECMO to the tertiary-care centre: thirty-two (37%) of 87 eligible patients with VA-ECMO insertion in remote hospitals survived to hospital discharge. Survival following the insertion of VA-ECMO for cardiogenic shock remains poor; however, it must be considered that in many of these cases, the predicted mortality rate before ECMO implantation exceeded 90%.

Refractory cardiac arrest represents another situation in which VA-ECMO is increasingly used. Insertion of ECMO during continuous cardiopulmonary resuscitation is also known as extracorporeal cardiopulmonary resuscitation (ECPR). Approximately one-half of patients experiencing resuscitated cardiac arrest die without return of spontaneous circulation (4,5). ECPR may represent the last chance for survival in these patients. Currently, there are controversial reports regarding VA-ECMO insertion for refractory cardiac arrest. Megarbane et al (6) reported long-term survival in three of 17 patients with refractory cardiac arrest and ECPR. Le Guen (7) reported that only two patients survived with good neurological outcome from 51 treated
with ECPR for refractory cardiac arrest. Conversely, Chen et al (8) observed an acceptable survival rate of 32% in 57 patients treated with ECPR. It appears that the outcomes of ECPR are worsening with the increasing time from collapse to ECMO initiation (9).

Several case series reported the use of VA-ECMO as support for high-risk percutaneous coronary and valvular intervention (10), arrhythmic storm, or electro-anatomical mapping and catheter ablation of nontolerated ventricular tachycardia (11). VA-ECMO has also been successfully used in sepsis-associated cardiomyopathy (12,13), pulmonary hypertension (14) and pulmonary embolism (15,16).

**LEFT VENTRICULAR OVERLOAD DURING VA-ECMO THERAPY**

VA-ECMO currently represents the most efficient minimally invasive circulatory support system. It provides sufficient support to enable adequate tissue perfusion even in cardiac arrest, and the hemodynamic efficacy is superior to other available percutaneous circulatory support systems such as Impella 2.5 (Abiomed Inc, USA) or TandemHeart™ (CardiacAssist, USA) (17). However, marked increase in systemic blood pressure caused by VA-ECMO may also impact left ventricular (LV) function. Increased LV afterload, together with severe systolic dysfunction, may result in LV overload with subsequent increase in left atrial pressure and severe pulmonary edema. It has been shown both in animal (18) and human (19) studies that increasing extracorporeal blood flow with VA-ECMO impairs several parameters of LV performance. VA-ECMO, therefore, represents a circulatory rather than LV assist device, and LV overload during VA-ECMO therapy represents a critical condition that frequently requires urgent intervention to unload the left ventricle. The present article summarizes current minimally invasive approaches to unload an overloaded left ventricle.

In the presence of severe LV dysfunction, the left ventricle is unable to eject a sufficient volume of blood against the increased afterload caused by the ECMO flow, resulting in impairment of various parameters of LV performance (18-20) and, in extreme situations, the aortic valve can remain closed even during systole. This results in LV overload with distention, increased wall stress and increased myocardial oxygen consumption (18-23). If cardiogenic shock has occurred as a result of decompensation in chronic heart failure, the left ventricle is likely to be compliant and the mitral valve is frequently incompetent as a result of chronic annular dilation and mitral valve leaflet tethering. The resultant mitral reflux would decompress the left ventricle to some extent, but may result in elevation of left atrial pressure and pulmonary edema (20,21,23,24). In contrast, in acute cardiogenic shock, such as following acute myocarditis or myocardial infarction, the left ventricle is likely to be noncompliant and the mitral valve likely to be competent. LV distension in this setting will result in a significant rise in intraventricular pressure and wall tension, which could be detrimental to damaged myocardium. In addition, the rise in LV pressure could reduce coronary blood flow, causing myocardial ischemia, particularly in the subendocardial area (20,25). The development of LV overload and distention could also be potentiated by the presence of aortic regurgitation (26).

**LEFT VENTRICLE UNLOADING**

To date, several approaches have been proposed to unload an overloaded left ventricle and decrease the elevated left atrial pressure on VA-ECMO therapy.

**Atrial septostomy**

Effective decompression of the left ventricle in the setting of VA-ECMO can be achieved by left-to-right shunt at the presence of atrial communication (atrial septal defect or patent foramen ovale); atrial shunt can be, however, created also artificially with percutaneous blade or balloon septostomy (22,24). Seib et al (24) reported series of 10 patients with severe LV dysfunction (seven myocarditis, three dilated cardiomyopathy) who required circulatory support with ECMO and who underwent left heart decompression with blade and balloon atrial septostomy (BBAS). BBAS was performed while on ECMO in seven patients and pre-ECMO in three. A femoral venous approach was used in all patients. Trans-septal puncture was required in nine patients while one patient had a patent foramen ovale. The procedure was successful in all patients and led to LV decompression and pulmonary decongestion. Left atrial mean pressure fell from a mean of 30.5 mmHg to 16 mmHg. Left atrial to right atrial pressure gradient fell from a mean of 20 mmHg pre-BBAS to 3 mmHg post-BBAS. Artificial atrial septal defect size ranged from 2.5 mm to 8 mm (24).

**Left atrial venting**

With guidance by bedside transesophageal echocardiography, a percutaneous atrial trans-septal cannula can be placed and connected to the inflow part of the ECMO circuit, thus, decompressing the left ventricle (27,28). Swartz et al (27) reported a case involving a 13-year-old girl who presented with cardiogenic shock. VA-ECMO was initiated, but after six days, severe LV distension resulted in decreased VA-ECMO flows. With guidance by bedside transesophageal echocardiography, a percutaneous atrial trans-septal cannula was placed and connected to the venous circuit, thus decompressing the left ventricle. The patient improved, was weaned from VA-ECMO five days later and was discharged from the hospital (27). Aiyagari et al (28) described a series of seven patients with cardiac failure on VA-ECMO with left atrial hypertension. All patients underwent left atrial decompression with trans-septal puncture and placement of a drain (8 Fr to 15 Fr). The median time from ECMO cannulation to left atrial decompression was 11 h. Average initial left atrial pressure was 31 mmHg. Successful drain placement was achieved in all patients with no major periprocedural complications. Echocardiographic improvement in left atrial dilation was achieved in five (71%) patients. Inability to decompress the left atrium was fatal in two patients. Four (57%) patients were decannulated and three (43%) survived to hospital discharge (28).

**LV venting**

The left ventricle can be vented directly by placing a transaortic vent through the axillary artery or by echocardiography-guided insertion of a pigtail catheter into the left ventricle through the aortic valve and connected to the inflow part of the ECMO circuit (29,30). Fumagalli et al (29) reported a case in which extracorporeal life support for cardiogenic shock was complemented with ventricular decompression achieved with a catheter placed percutaneously through the aortic valve into the left ventricle. The blood drained from the left ventricle was pumped into the femoral artery. The normalization of left heart filling pressures led to the resolution of pulmonary edema, and the patient underwent a successful heart transplantation after seven days of mechanical cardiocirculatory support (29). Barbone et al (30) proposed LV unloading with a 7 Fr pigtail catheter inserted into the left ventricle via the femoral artery contralateral to the arterial outflow cannula. Using this approach, they were able to support three different patients, resolving LV distension and preventing lung congestion without major complications.

**Pulmonary artery drainage**

An alternative approach to LV decompression is the percutaneous insertion of a venous cannula into the pulmonary artery and connection of this cannula to the inflow part of the ECMO circuit (23,31). Avali et al (31) reported a case involving a 43-year-old woman treated with ECMO for refractory cardiogenic shock after left pneumonia and severe sepsis. A 15 Fr venous cannula was placed percutaneously to the pulmonary artery and connected to the ECMO circuit to decompress the left heart, and to facilitate LV function. After myocardial recovery, the patient was weaned and ECMO was removed on day 16 (31). Fouilloux et al (23) described unloading of the left ventricle with a cannula inserted into the pulmonary trunk through the inferior vena cava with a femoral approach in two-year-old girl with a restrictive cardiomyopathy. A few hours later, the chest x-ray improved and five
INTRA-OARTIC BALLOON PUMP

Intra-aortic balloon pump (IABP) counter-pulsation is a device that inflates and deflates a 30 cm to 50 cm balloon in the descending aorta. The balloon inflations and deflations are synchronized with cardiac cycle and, therefore, deflation just before systolic ejection may decrease afterload and improve LV ejection. Moreover, increased diastolic pressure on IABP could also improve coronary blood flow. Despite the controversial data from the Intra-Aortic Balloon Pump in cardiogenic SHOCK (IABP-SHOCK) II trial (32), IABP currently remains one of the most commonly used mechanical circulatory support devices in the treatment of acute heart failure. When administerd in a timely manner, it can play a critical role in the rescue of patients with acute myocardial damage. It has been shown in animal models that insertion of IABP during VA-ECMO support may improve several parameters of LV performance (33). Currently, several centres use IABP to reduce LV afterload during VA-ECMO therapy. In a group of 219 patients treated with VA-ECMO after cardiac surgery, Doll et al (34) found that use of IABP during ECMO support was associated with a significantly higher survival rate. Ma et al (35) reported 54 adult patients with acute heart failure who received combined ECMO and IABP support, all of whom showed improvements in terms of overall circulation. Thirty-four of the patients were successfully weaned from mechanical circulatory support, and 21 (39%) survived to hospital discharge (35). The study by Petroni et al (36) showed that adding an IABP to peripheral VA-ECMO was associated with improved LV function. Discontinuation of intra-aortic balloon pumping was associated with higher pulmonary artery wedge pressure (19±10 versus 29±22 mmHg; P=0.01), increased LV end-systolic (51±13 versus 50±14 mmHg; P=0.05) and end-diastolic (55±13 versus 52±14 mmHg; P=0.03) diameters, and decreased pulse pressure (15±13 versus 29±22 mmHg; P=0.02) (36). In contrast, Park et al (37) did not find any mortality or morbidity benefit with IABP in the group of 96 VA-ECMO-treated patients with cardiogenic shock due to acute myocardial infarction.

PERCUTANEOUS LV SUPPORT DEVICES

Impella LP 2.5 (Abiomed Inc, USA) is a catheter-based transaortic axial flow pump that can be introduced through a percutaneous femoral approach. The device is placed across the aortic valve and pumps up to 2.5 L/min of blood from the left ventricle to the ascending aorta. Koeckert et al (25) reported the use of Impella LP 2.5 for left ventricle decompression in a 70-year-old man with decompensated heart failure who was placed on VA-ECMO for cardiogenic shock with severe pulmonary edema and respiratory failure. Both devices were successfully weaned on day 5 after myocardial recovery (25). Narain et al (38) described a case involving 31-year-old man with fulminant myocarditis treated with the Impella device and VA-ECMO. On full mechanical circulatory support, the hemodynamic status improved and both systems were explanted after 48 h (38).

CONCLUSIONS

Despite the advances in critical care during the past years, the mortality rate associated with rapidly progressing or severe refractory cardiogenic shock remains high and mechanical circulatory support is often the last chance for survival. An increasing body of evidence supports the use of VA-ECMO in these critical conditions. However, especially in patients with most severe heart dysfunction, initiation of VA-ECMO may be associated with LV overload with all of its consequences including severe pulmonary edema and respiratory failure. Current options for minimally invasive LV unloading during VA-ECMO therapy are very limited; however, to date, several techniques have been described with promising results.

ACKNOWLEDGEMENTS: This work was supported by an Institutional grant MH CZ - DRO (Nemocnice Na Homolce – NNH, 00023884).

REFERENCES


